THP shows noninferior pCR rates compared to TCbHP in HER2-positive invasive breast cancer
Trial shows omitting carboplatin maintains success in breast cancer
This Phase III randomized controlled trial of 766 women with untreated, stage II and III, HER2-positive invasive breast cancer found that th…
A new clinical trial shows that removing one specific drug can lower severe side effects while maintaining high success rates for certain br…
Tucatinib plus trastuzumab and pertuzumab improves median PFS to 24.9 months in HER2+ MBC
Trial shows Tucatinib improves progression-free survival for metastatic breast cancer
This Phase III randomized controlled trial of 654 patients with HER2+ metastatic breast cancer found that adding tucatinib to trastuzumab an…
Adding tucatinib to a standard two-drug combination may help patients with HER2+ metastatic breast cancer live longer without their disease …
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Trastuzumab emtansine and trastuzumab deruxtecan use in three patients with ERBB2-amplified rare tumors
Rare tumors respond to targeted antibody drug treatments
This retrospective case series evaluated three patients with ERBB2-amplified rare tumors, including periampullary, salivary duct, and poorly…
Three patients with rare, aggressive cancers saw significant tumor shrinkage after receiving targeted antibody drug therapies.
FDA Approves Perjeta (pertuzumab) for HER2-Positive Breast Cancer
FDA approves new drug Perjeta for HER2-positive breast cancer
The FDA approved Perjeta (pertuzumab) for use in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer an…
The FDA approved Perjeta (pertuzumab) for HER2-positive breast cancer.
QDB method shows higher consistency than IHC for HER2 assessment in invasive breast cancer
New Test Finds Hidden Breast Cancer Targets
This observational cohort study compared a Quantitative Dot Blot (QDB) method to immunohistochemistry (IHC) for HER2 assessment in patients …
Some women told their breast cancer lacks a key target may actually benefit from powerful drugs — a new test can finally tell the difference…
Retrospective analysis identifies risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients
Many Breast Cancer Patients Can Avoid Heart Damage — If Doctors Know the Warning Signs
This retrospective analysis of 298 HER2-positive breast cancer patients assessed trastuzumab-induced cardiotoxicity.
This could help doctors protect patients’ hearts before cancer therapy even begins.
Phase II trial protocol examines HER2-PET imaging to predict trastuzumab deruxtecan response in HER2-low metastatic breast cancer
A Full-Body Scan May Soon Decide Who Benefits From This Breast Cancer Drug
A multicenter, prospective, open-label phase II trial protocol will enroll 70 patients with HER2-low metastatic breast cancer.
A whole-body imaging scan may one day replace a single biopsy for matching patients to targeted breast cancer therapy.
Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients
Can a shorter, more intense chemo regimen help prevent early-stage HER2-positive breast cancer from returning?
A phase II trial evaluated a dose-dense regimen of cyclophosphamide, paclitaxel, and trastuzumab after surgery in 20 patients with stage I-I…
For women with early-stage HER2-positive breast cancer, a key question is whether a shorter, more intense chemotherapy schedule after surger…